Q-omics provides the consensus-scored YWHAG profile across patient tissues and cancer cell-line models. YWHAG expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, YWHAG is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, YWHAG protein abundance shows 22,612 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where YWHAG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YWHAG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YWHAG survival associations across molecular data types. YWHAG RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YWHAG RNA expression–survival associations across cancer types. High YWHAG expression shows unfavorable associations in KIRP, MESO, LUAD, CESC, HNSC and KICH. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for YWHAG RNA expression.
This table summarizes YWHAG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for YWHAG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YWHAG shows higher tumor expression in HNSC, KIRC, KIRP, COAD, LIHC and LUAD. The HNSC box plot shows higher YWHAG RNA expression in tumor versus normal tissue (log2 FC = +1.212, t-test p < 0.001).
This table shows molecular features associated with YWHAG in patient tissues and cancer cell lines. In patient samples, YWHAG shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, YWHAG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Lymphoma.
